Definium Therapeutics (DFTX) Short-term Investments (2025 - 2026)
Definium Therapeutics (DFTX) reported Short-term Investments of $110.9 million for Q1 2026, down 14.42% year-over-year from $129.6 million in Q1 2025, and down 27.87% on a QoQ basis from $153.8 million in Q4 2025.
Definium Therapeutics (DFTX) has 2 years of Short-term Investments data on file, last reported at $110.9 million in Q1 2026.
- Quarterly Short-term Investments fell 14.42% year-over-year to $110.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.9 million (down 14.42% YoY) and the FY2025 annual result came in at $153.8 million, changed N/A from the prior year.
- Short-term Investments retreated to $110.9 million in Q1 2026 per DFTX's latest filing, from $153.8 million in the prior quarter.
- Across five years, Short-term Investments topped out at $189.1 million in Q3 2025 and bottomed at $110.9 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110.90 Mn |
| Dec 31, 2025 | 153.76 Mn |
| Sep 30, 2025 | 189.10 Mn |
| Jun 30, 2025 | 149.60 Mn |
| Mar 31, 2025 | 129.59 Mn |